Tolerability of a New Fast Updosed Immunologically Enhanced Subcutaneous Immunotherapy Formulation With an Optimized Allergen to Adjuvant Ratio Under Routine Practice Conditions: A Noninterventional Observational Study

B Hauswald,1 H Wolf,2 F Becker,3 S Becker,3 J Schnitker,4 E Wüstenberg1,2

1Universitätsklinikum Carl Gustav Carus, Clinic for Otolaryngology, Dresden, Germany
2ALK-Abelló Arzneimittel GmbH, Clinical Development/Medical & Regulatory Affairs, Hamburg, Germany
3ENT-physicians, Hamburg, Germany
4Institut für angewandte Statistik GmbH, Bielefeld, Germany

Abstract

Background and objectives: A fast updosed immunologically enhanced subcutaneous immunotherapy (SCIT) formulation with an optimized allergen to aluminium hydroxide ratio was first introduced in September 2009 in Germany. A large randomized controlled trial showed that the formulation had considerable immunologic effects and good tolerability. In this open-label, uncontrolled, noninterventional study, tolerability was investigated during routine application.

Patients and methods: Patients with allergic rhinoconjunctivitis and/or asthma were treated with pollen and mite allergens using a 5-injection updosing schedule (AVANZ®: 300, 600, 3000, 6000 and 15 000 SQ+ units) with weekly intervals, followed by a maintenance schedule with injections of 15 000 SQ+ units. Adverse events (AEs) were recorded by physicians, and symptoms and use of symptomatic medication were analyzed before the start of therapy and after an average 8-month treatment period.

Results: SCIT was documented by 362 allergists in 1036 patients between September 2009 and February 2011. AEs mainly consisted of local reactions during updosing (in 24.5% of patients). Systemic reactions were observed during updosing (8.4%) and maintenance therapy (1.7%), the most frequent of which was dyspnea. Overall, tolerability and the effect of treatment were rated as good or very good by 94.9% and 86.6% of patients and by 96.2% and 89.6% of physicians, respectively.

Conclusions: In this open-label, noninterventional study, fast updosed immunologically enhanced SCIT (AVANZ®) was well tolerated in a large group of patients.

Key words: Adjuvant. Immunomodulators. Immunology. Short updosing. Subcutaneous immunotherapy. Tolerability.
Introduction

The prevalence of allergic diseases, including allergic rhinitis and asthma, has been increasing over the last 2 decades [1]. Specific immunotherapy (SIT) is the only treatment modality capable of influencing the natural course of allergic disease, at best preventing progression [2]. It has the potential to halt progression from rhinitis to asthma, at least in the case of products containing intact allergens combined with aluminium hydroxide [3]. Treatment involves repeated administrations of specific allergen extracts with the aim of inducing immunologic tolerance and reducing symptoms on subsequent natural allergen exposure to achieve a long-term treatment effect and improve quality of life [4].

The clinical effectiveness of subcutaneous immunotherapy (SCIT) is well established and has been demonstrated in a meta-analysis [5]. However, the long updosing phases necessary in conventional SCIT with intact nonmodified allergens over a period of several weeks can make treatment inconvenient for patients, as well as for centers with large numbers of patients [6].

Aluminium hydroxide, which is widely used in SCIT for slow allergen release, has also been identified as an adjuvant. The mode of action is still not completely understood but it may be effective through danger signals via activation of the NLRP3 inflammasome complex [7-10].

To improve the convenience of SCIT, a new fast updosed immunologically enhanced SCIT formulation (AVANZ) with an optimized allergen to aluminium hydroxide ratio was developed to allow for the administration of lower doses and thus shorter updosing schedules while maintaining the immunogenicity compared to traditional SCIT. The maintenance dose of this formulation is reduced to 15 000 SQ+ units compared to the recommended maximum maintenance dose of 100 000 SQ units with traditional SCIT (Alutard SQ); concentrations of aluminium hydroxide and other excipients are kept at the same level [6].

The immunologic efficacy of the new fast updosed immunologically enhanced SCIT formulation was demonstrated to be equivalent to traditional SCIT [6,11]. It became available as a Named Patient Product for routine use in Germany in 2009, in Italy in 2010, and in Spain and Austria in 2011.

Systematically recorded data on the application and tolerability of the new formulation in real life, however, are needed to evaluate the risks and benefits of the new product in daily use.

The objective of the present observational study was to systematically record data on tolerability of the new SCIT product for a large group of patients treated with pollen and mite allergens under routine practice conditions.

Patients and Methods

In this multicenter, open-label, noninterventional observational study, we recorded updosing with 5 injections of an immunologically enhanced allergen product and subsequent maintenance injections for a total treatment period of up to 1 year. The main study visits were performed at the start of updosing and at the end of the observation period.

The centers participating in this study were distributed evenly across Germany. For this purpose allergists applying SIT were registered in regional lists and asked to participate in the study following random rearrangement of the list. Each center was asked to record data for 3 consecutively recruited patients who agreed to participate in the study. Together, the random selection of the centers and the consecutive enrolment of study patients represent a suitable measure to avoid selection bias in the study population. Physicians were asked to note down all patients who were potentially eligible for the study in a patient’s log to ensure the selection process remained fully transparent.

The study was conducted in 362 allergy centers in Germany between September 2009 and February 2011 and included 1036 patients with type I allergies caused by various pollen allergens or mites; most of the patients had allergic rhinoconjunctivitis with or without asthma. All the patients with a type I allergy mediated by pollen allergens or mites and an indication for SIT for whom the decision to apply SCIT with the immunologically enhanced formulation (AVANZ) had been taken independently of the study were eligible for documentation in the study.

At inclusion, the physicians recorded each patient’s allergy history, with inclusion of the following information: age at first onset of allergic complaints, age when the allergy was first diagnosed, clinical manifestations of the allergy (rhinitis/conjunctivitis/bronchial asthma/atopic dermatitis/others, if applicable), concomitant allergies, previous courses with SIT, and the diagnostics applied for the allergen treated by SCIT. Symptoms and medication use in the previous season or previous period before SCIT was started were assessed retrospectively. Symptoms affecting the nose, eyes, and bronchi were graded as absent/mild (transient symptoms,
no interference with the patient's daily activities), moderate (marked symptoms, mild interference), or severe (considerable symptoms, unacceptable interference). Use of concomitant symptomatic medication was classified as no medication, topical or oral antihistamines, topical, oral, or inhaled corticosteroids, inhaled β-sympathomimetics, or other.

At the final visit overall tolerability (very good, good, moderate, or poor) and continuation of treatment beyond the end of the observation period were assessed.

Patients were treated with birch, tree mix, grass mix and rye, mite mix, timothy, or mugwort allergens (Table 1). The prescription and the use of AVANZ were subject to individual treatment needs at the discretion of the physician. Allergen extracts were standardized by ALK according to internal standards; the biological activity was determined as previously described [13,14] and expressed in immunologically enhanced standardized quality (SQ+) units. SCIT was initiated using a 5-step updosing schedule (300, 600, 3000, 6000, 15 000 SQ+) at injection intervals of 1 week. Updosing was followed by maintenance treatment with 15 000 SQ+; the first dose was administered after 2 weeks and thereafter at intervals of 6±2 weeks.

Data were recorded during regular visits to the clinic. For each injection the dose and the applied volume were recorded and a note was made of whether anti-allergic premedication had been used prior to injection.

For assessment of tolerability, all adverse events (AEs) were collected and recorded according to diagnosis or description, time of onset postinjection, duration, severity, causality with injection, medical measures taken, outcome, seriousness, and discontinuation, if applicable. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA). They included local and systemic reactions, other AEs not attributable to single injections, and serious AEs (SAEs). Adverse drug reactions were defined as either immediate (occurring 0-30 minutes after injection) or delayed (occurring >30 minutes after injection).

An AE was assessed as severe when the event considerably interfered with the patient's daily activities. A serious AE was defined as any medical occurrence or effect that was life-threatening, required hospitalization or prolongation of hospitalization, resulted in persistent or significant disability or incapacity, resulted in death, congenital abnormalities, or birth defects, or any other event judged medically important.

**Statistical Analysis**

Statistical analyses were performed using SAS software, versions 8.2, 9.1.3, and 9.2 (SAS Institute). Data were analyzed by descriptive statistical methods using minimum, maximum, median, mean and SD for continuous data as well as frequency distributions for ordinal data. AEs were displayed for patients and for the frequency of events including multiple occurrences by patient. The sample size was planned to be at least 900 in order to detect adverse drug reactions of low incidence (0.5%) with high probability (99%) at least once. We therefore aimed to include at least 300 physicians, each recording data for 3 patients, in the study. The All-Patients-Treated set was stratified with respect to the allergen used, especially birch, tree mix, grass mix and rye, and mite mix.

**Results**

**Patients**

Data for 1036 patients treated with 1 of the allergens— birch, tree mix, grass mix, mite mix, timothy grass, or mugwort (see Figure 1)—were evaluated with respect to tolerability for the updosing phase of treatment; 947 patients continued with the maintenance treatment. The average duration of treatment was 225 days with a median of 11.0 injections. The patients' characteristics are shown in Table 1.

**Figure 1. Flow of patients through the study. SCIT indicates subcutaneous immunotherapy.**
Updosing with a maximum of 5 injections according to the recommended dose schedule was applied in 833 patients (80.4%); 1 additional injection was given to 136 patients (13.1%), 2 to 38 patients (3.7%) and more than 2 to 29 patients (2.8%). Antihistamine premedication prior to injections during updosing was used in 6.9% of patients.

Adverse Events

AEs were reported in 24.5% of the 1036 patients. The overall data for local and systemic reactions as well as for all adverse reactions are shown in detail in Table 2. The proportion of patients with AEs including adverse reactions and other AEs for the different allergens applied is shown in Table 1.

Table 1. Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Birch</th>
<th>Tree mix</th>
<th>Grass mix</th>
<th>Mite mix</th>
<th>All patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, No.</td>
<td>86</td>
<td>351</td>
<td>382</td>
<td>204</td>
<td>1036</td>
</tr>
<tr>
<td>Age, median (range), y</td>
<td>36.5 (9-67)</td>
<td>40.0 (10-72)</td>
<td>33.0 (9-79)</td>
<td>29.5 (7-80)</td>
<td>36.0 (7-80)</td>
</tr>
<tr>
<td>Sex, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>39 (45.3)</td>
<td>171 (48.7)</td>
<td>191 (50.0)</td>
<td>93 (45.6)</td>
<td>501 (48.4)</td>
</tr>
<tr>
<td>Female</td>
<td>47 (54.7)</td>
<td>180 (51.3)</td>
<td>191 (50.0)</td>
<td>111 (54.4)</td>
<td>535 (51.6)</td>
</tr>
<tr>
<td>BMI, mean (SD), kg/m²</td>
<td>25.2 (5.2)</td>
<td>24.8 (3.8)</td>
<td>24.6 (4.0)</td>
<td>24.0 (3.4)</td>
<td>24.6 (4.0)</td>
</tr>
<tr>
<td>Duration since diagnosis of the pollen/mite allergy, mean (SD), y</td>
<td>5.9 (7.7)</td>
<td>7.5 (9.5)</td>
<td>6.8 (8.6)</td>
<td>5.4 (7.8)</td>
<td>6.7 (8.8)</td>
</tr>
<tr>
<td>Moderate/severe nose symptoms, No. (%)</td>
<td>75 (87.2)</td>
<td>328 (93.4)</td>
<td>359 (94.0)</td>
<td>178 (87.3)</td>
<td>953 (92.0)</td>
</tr>
<tr>
<td>Moderate/severe eye symptoms, No. (%)</td>
<td>68 (79.1)</td>
<td>266 (75.8)</td>
<td>274 (71.7)</td>
<td>99 (48.5)</td>
<td>715 (69.0)</td>
</tr>
<tr>
<td>Asthma, No. (%)</td>
<td>27 (31.4)</td>
<td>117 (33.3)</td>
<td>101 (26.4)</td>
<td>51 (25.0)</td>
<td>300 (29.0)</td>
</tr>
<tr>
<td>History of immunotherapy, %</td>
<td>37.2</td>
<td>39.9</td>
<td>29.8</td>
<td>29.4</td>
<td>34.3</td>
</tr>
<tr>
<td>Symptomatic medication in the last season/previous year, %</td>
<td>80.2</td>
<td>83.7</td>
<td>80.1</td>
<td>65.0</td>
<td>78.2</td>
</tr>
</tbody>
</table>

aIncluding timothy (n=11) and mugwort (n=2).

Table 2. Overview of All Local, Systemic and Adverse Reactions in 1036 Patients

<table>
<thead>
<tr>
<th></th>
<th>Local Reactions</th>
<th>Systemic Reactions</th>
<th>All Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>All reactions</td>
<td>164 (15.8) 588</td>
<td>100 (9.7) 237</td>
<td>230 (22.2) 825</td>
</tr>
<tr>
<td>During updosing</td>
<td>150 (14.5) 432</td>
<td>87 (8.4) 209</td>
<td>210 (20.3) 641</td>
</tr>
<tr>
<td>During maintenance</td>
<td>42 (4.4) 156</td>
<td>16 (1.7) 28</td>
<td>54 (5.7) 184</td>
</tr>
<tr>
<td>≤30 min after injection</td>
<td>71 (6.9) 237</td>
<td>23 (2.2) 55</td>
<td>88 (8.5) 292</td>
</tr>
<tr>
<td>&gt;30 min after injection</td>
<td>82 (7.9) 312</td>
<td>64 (6.2) 150</td>
<td>124 (12.0) 462</td>
</tr>
<tr>
<td>Missing values</td>
<td>11 (1.1) 39</td>
<td>13 (1.3) 32</td>
<td>18 (1.7) 71</td>
</tr>
<tr>
<td>Unlikely causality</td>
<td>1 (0.1) 6</td>
<td>18 (1.7) 29</td>
<td>15 (1.4) 35</td>
</tr>
<tr>
<td>Possible causality</td>
<td>163 (15.7) 582</td>
<td>82 (7.9) 208</td>
<td>215 (20.8) 790</td>
</tr>
<tr>
<td>Intensity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>96 (9.3) 398</td>
<td>53 (5.1) 103</td>
<td>131 (12.6) 501</td>
</tr>
<tr>
<td>Moderate</td>
<td>46 (4.4) 144</td>
<td>31 (3.0) 95</td>
<td>69 (6.7) 239</td>
</tr>
<tr>
<td>Severe</td>
<td>22 (2.1) 42</td>
<td>15 (1.4) 35</td>
<td>30 (2.9) 77</td>
</tr>
<tr>
<td>Missing values</td>
<td>– 4</td>
<td>1 (0.1) 4</td>
<td>– 8</td>
</tr>
<tr>
<td>Treated by medication</td>
<td>41 (4.0) 100</td>
<td>48 (4.6) 119</td>
<td>77 (7.4) 219</td>
</tr>
<tr>
<td>Serious</td>
<td>– 6 (0.6) 39</td>
<td>– 6 (0.6) 39</td>
<td>– 6 (0.6) 39</td>
</tr>
<tr>
<td>Treatment terminated</td>
<td>9 (0.9) 12</td>
<td>17 (1.6) 52</td>
<td>23 (2.2) 64</td>
</tr>
</tbody>
</table>

Data shown as No. (%) of patients and No. of events.
in Table 3. The treatment was terminated due to AEs in 3.0% of patients. The majority of reactions were assessed to be causally related to the treatment. AEs were mild in 13.0% of patients, moderate in 8.1%, and severe in 3.2%; 8.5% of patients with AEs were treated with medication. AEs related to treatment and observed in 1% or more of patients are displayed in Figure 2. Local reactions at the injection site, such as swelling, erythema, and pruritus were reported with the highest frequency; systemic reactions were much less common, with dyspnea (1.2%), allergic rhinitis (1.0%), and pruritus (1.0%) as the most frequent reactions. The highest rates of local and systemic reactions were observed during updosing at the dose of 3000 SQ+ and considerably lower rates were seen during maintenance therapy with 15000 SQ+. Overall tolerability of treatment was assessed as good or very good by 94.9% of patients and 96.2% of physicians. Serious AEs were reported in 11 patients and were related to treatment in 6 of these. Of these 6 SAEs, 2 were classified as immediate reactions and 4 as delayed reactions. The immediate reactions were reported in a 51-year-old woman who developed tachycardia, hypotension, dyspnea, and chest tightness 2 minutes after the injection of a 6000 SQ+ dose and in an 18-year-old woman who experienced high blood pressure, generalized itching, and dizziness 10 minutes after the first injection (dose 3000 SQ+); both reactions were related to tree mix and classified as medically important. The patients recovered after treatment with antihistamines and corticosteroids and discontinued treatment. Delayed reactions (1-5 hours after injection) were reported in 1 woman and 3 men who had been treated with birch, timothy grass, or grass mix (2 patients). They showed symptoms of facial swelling, edema, and urticaria in addition to breathing difficulties in 1 case (duration 2-3 hours, treatment continued) and bronchospasm and dyspnea in another (duration 12 hours, treatment discontinued). The dose was 3000 SQ+ in all cases. These patients visited a hospital acute day ward, recovered after treatment with antihistamines and corticosteroids, and were hospitalized overnight for observation. Adrenaline was not used in any of the patients with SAEs.

Discussion

This study was initiated to evaluate tolerability with a new immunologically enhanced SCIT product with pollen and house dust mite allergens under real-life conditions. The prospective, open-label observational design was appropriate to record data on the routine use of SCIT in a real-life setting. In the course of this study, data for routine application of a fast updosed immunologically enhanced immunotherapy formulation with an optimized ratio of allergen and aluminium hydroxide as adjuvant (AVANZ) were recorded in 1036 patients treated with one of various pollen or house dust mite allergens. The study was started when the product became available in Germany as a Named Patient Product in September 2009 and, therefore, reflects the first systematically recorded data for the routine application of various allergens. Data from a previous controlled clinical trial in 400 patients treated with...
5 injections for updosing of 4-grass and rye allergens with weekly or 3-to-4 day intervals and 2 maintenance injections revealed significant immunologic effects and a favorable safety and tolerability profile [6].

The severity of symptoms in the patients in our study was assessed according to ‘marked symptoms with mild interference with daily activities’ as the criterion for moderate and ‘unacceptable symptoms that considerably interfered with daily activities’ as the criterion for severe symptoms. According to these criteria, 92.0% of all the patients treated had moderate to severe nasal symptoms (birch, 87.2%; tree mix, 93.5%; grass mix, 94.0%; mite mix, 87.2%). Moderate to severe eye symptoms were recorded in 69.0% of the patients (birch, 79.1%; tree mix, 75.7%; grass mix, 71.7%; mite mix, 48.5%). Use of symptomatic medication in the previous season or previous year was reported in 78.2% of the patients (birch, 80.2%; tree mix, 83.7%; grass mix, 80.1%; mite mix, 65.0%) and thus appears to be low when compared with the percentage of patients who were assessed as having moderate to severe rhinoconjunctivitis symptoms, ie, patients treated with mite allergens. Due to the noninterventional design of our study, patients were not selected according to inclusion and exclusion criteria for the severity of rhinoconjunctivitis symptoms and use of symptomatic medication, but were treated at the discretion of the physician, reflecting the current practice for the use of SCIT in Germany. The characteristics of patients treated with grass mix in our study are similar to those reported in another large noninterventional, observational study with SCIT in patients allergic to grass pollen conducted in Germany [12]. During the observation period of our study, patients were treated for approximately 8 months and received a median of 11 injections. The recommended dosage schedule of 5 injections was followed in the majority of patients (80.4%). Data for maintenance treatment were available for more than 90% of the patients treated initially.

The application of the SCIT injections was generally well tolerated. AEs were reported in 24.5% of all patients treated throughout the observation period; the frequency was highest during updosing and was considerably lower during maintenance therapy. The most frequent AEs were mild to moderate local reactions such as swelling and erythema at the injection site (in 15.8% of patients). Less frequent AEs related to treatment were systemic reactions, seen in 7.9% of patients; the most common of these were dyspnea (1.2% of patients), allergic rhinitis (1.0%), and pruritus (1.0%). The highest frequency of local reactions was reported for grass mix (19.4% of patients) and lower frequencies were seen for mite mix (12.3%) and tree mix (13.4%). Systemic reactions were observed with mite mix in 11.8% of patients and with birch in 10.5%, grass mix in 9.9% and tree mix in 7.7% of patients. In the controlled trial in which 201 patients had been treated with grass mix at weekly intervals during updosing, local reactions were recorded in 36% of patients and systemic reactions in 21%. As to be expected for a noninterventional, observational study, lower rates of local and systemic reactions were reported during routine use of the product than in the controlled clinical trial. Similarly to in the trial, delayed reactions (local and systemic reactions >30 minutes after injection) were also more common than immediate reactions in our study (12% vs 8.5%). Most systemic reactions were rated as mild (5.1%) or moderate (3.0%); they were severe in 1.4% of patients and treatment was discontinued in 1.6% of patients. Therefore, overall tolerability does not seem to be affected by the occurrence of delayed reactions given that severe reactions were only observed in a few patients. SAEs related to treatment were recorded in 6 (0.6%) of the 1036 patients; they were immediate reactions in 2 cases and delayed reactions in 4. Patients with delayed reactions were hospitalized overnight for observation in 4 cases and treatment was continued in 3 cases and discontinued in 1. Local and systemic reactions were most frequently reported for the third injection of the updosing schedule (dose 3000 SQ+). Depending on the severity of the reaction it is recommended to repeat the last dose or reduce the dose by 1 to 3 steps in the dosage schedule. Good or very good overall tolerability assessments by patients and physicians were obtained for about 95% of patients. The pattern of AEs observed in our study was in line with patterns reported in the controlled trial with the same product [6] and previous trials using non-modified aluminium hydroxide-adsorbed grass pollen allergens [15,16]. In the randomized controlled clinical trial significant immunologic effects from the induction of immunoglobulin (Ig) G4 antibodies and IgE-blocking factor as a functional assay of serum IgG-associated inhibitory activity have been detected [6]. In a recent analysis of immunologic data from the trial published by Frew et al [15], a modest but significant inverse relationship was demonstrated between postimmunotherapy serum inhibitory activity and combined symptom-rescue medication scores. However, this has not been observed for immune reactive IgG4 levels [17], suggesting that an increase in IgE-blocking factor may predict clinical efficacy.

In conclusion, in this noninterventional, open-label, observational study, therapy with various pollen and mite allergens of the new hypoallergenic fast updosed product with an optimized ratio of allergen and aluminium hydroxide as adjuvant was observed to be well tolerated in a large number of patients during routine treatment, although a number of patients experienced predominantly mild to moderate delayed systemic reactions.

Acknowledgments

The authors would like to thank all physicians who provided data on treatment of their patients for the study. We also thank Sabine Quast who provided editorial and journal submission assistance.

Funding

ALK-Germany sponsored this trial. The company was involved in trial design, data collection, analysis, and interpretation. Medical writing, editorial, and journal submission assistance from Sabine Quast was funded by the sponsor. The investigators received remuneration from ALK for the documentation of treatment of the patients. As a clinical research organization, IAS GmbH received remuneration from ALK for its services in biometrical planning, data management, and statistical analysis of the data.
**Conflicts of Interest**

B Hauswald received remuneration from ALK for the documentation of patient data from her clinic for this study. Hendrik Wolf, et al received remuneration from ALK for the documentation of patient data from their clinic for this study. J Schnitker is Managing and Scientific Director of the clinical research organization IAS GmbH, which was funded from ALK for this study. H Wolf and E Wüstenberg are employees of ALK.

**Previous Presentation**


**References**


**Manuscript received December 19, 2012; accepted for publication March 13, 2013.**

**Hendrik Wolf**
ALK-Abelló Arzneimittel GmbH
Griessstr. 75, Haus 25
D-22763 Hamburg, Germany
E-mail: hendrik.wolf@alk.net